A Phase I, Open-Label, Randomized, 2-way Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of a Single Oral Dose of JNJ-47910382 Formulated as a Tablet and as a Suspension
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2012
At a glance
- Drugs JNJ 47910382 (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 13 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2012 New trial record